Revlimid and Breastfeeding
It is unknown if Revlimid (lenalidomide) passes through breast milk. However, based on the properties of this drug, it is thought that it would pass through breast milk to some extent. Because this medication has the potential for causing dangerous complications, such as infections and bleeding problems, healthcare providers will likely advise women to avoid breastfeeding during Revlimid treatment.
Can Breastfeeding Women Take Revlimid?
Revlimid® (lenalidomide) is a prescription medication used to treat multiple myeloma (cancer of the bone marrow) and anemia due to certain types of bone marrow diseases known as myelodysplastic syndromes. It is also approved to treat mantle cell lymphoma.
It is unknown whether Revlimid passes through breast milk. Therefore, if you are breastfeeding or plan to start, talk to your healthcare provider prior to taking this medication.
More Information About Revlimid and BreastfeedingNo research has been done on using Revlimid while breastfeeding. Therefore, it is unknown whether the medication would be found in breast milk, or what its potential effects on a nursing infant would be. Based on the properties of the medication, it is expected to pass through breast milk to some extent.
While the lack of information on Revlimid and breastfeeding is certainly frustrating, it is important to understand that studies of medications are rarely done in breastfeeding women. This is because the studies would usually expose an infant, who will not directly benefit from the medication, to possible risks.
Revlimid is associated with several potentially serious side effects, including decreased white blood cell counts and platelets (which could increase the risk for infection and bleeding), and blood clots in the veins and legs. The potential for these and other Revlimid side effects cannot be completely ruled out in a nursing infant until more information is available. Therefore, it is probably safest for women to avoid breastfeeding during Revlimid treatment.